Even patients who respond well to initial therapy with ALK inhibitors may experience tumor recurrence because of acquired resistance to these drugs via multiple mechanisms, including secondary ALK resistance mutations and tumor growth promoting molecular pathways. The gene discussed is ALK; the disease is neoplasm.